An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Puma Biotechnology, Inc.
Information provided by (Responsible Party):
Puma Biotechnology, Inc. Identifier:
First received: September 26, 2013
Last updated: September 15, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)